TB
Therapeutic Areas
Interpace Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ThyGeNEXT® + ThyraMIR®v2 Combined Strategy | Risk-stratification of indeterminate thyroid nodules | Commercial |
| PancraGEN® | Pancreatic cyst risk assessment | Commercial |
| Drug | Indication | Phase |
|---|---|---|
| ThyGeNEXT® + ThyraMIR®v2 Combined Strategy | Risk-stratification of indeterminate thyroid nodules | Commercial |
| PancraGEN® | Pancreatic cyst risk assessment | Commercial |